156 related articles for article (PubMed ID: 28634311)
1. [Bevacizumab-Related Hyperintense Lesions on Diffusion-Weighted Imaging at Different Locations in a Patient with Malignant Glioma].
Oshiro S; Wakuta N; Kawai S; Miki K; Shigemori Y
No Shinkei Geka; 2017 Jun; 45(6):509-517. PubMed ID: 28634311
[TBL] [Abstract][Full Text] [Related]
2. Comparative Histologic and Molecular Analysis of 2 Recurrent Lesions Showing Different Magnetic Resonance Imaging Responses After Bevacizumab Treatment: Report of a Case of Anaplastic Astrocytoma.
Otani Y; Ichikawa T; Uneda A; Kurozumi K; Ishida J; Date I
World Neurosurg; 2018 Aug; 116():464-471.e1. PubMed ID: 29772361
[TBL] [Abstract][Full Text] [Related]
3. The Development of Reduced Diffusion Following Bevacizumab Therapy Identifies Regions of Recurrent Disease in Patients with High-grade Glioma.
Barajas RF; Butowski NA; Phillips JJ; Aghi MK; Berger MS; Chang SM; Cha S
Acad Radiol; 2016 Sep; 23(9):1073-82. PubMed ID: 27443507
[TBL] [Abstract][Full Text] [Related]
4. Radiographic patterns of progression with associated outcomes after bevacizumab therapy in glioblastoma patients.
Cachia D; Elshafeey NA; Kamiya-Matsuoka C; Hatami M; Alfaro-Munoz KD; Mandel JJ; Colen R; DeGroot JF
J Neurooncol; 2017 Oct; 135(1):75-81. PubMed ID: 28702781
[TBL] [Abstract][Full Text] [Related]
5. Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumab.
Thomas A; Rosenblum M; Karimi S; DeAngelis LM; Omuro A; Kaley TJ
CNS Oncol; 2018 Jan; 7(1):7-13. PubMed ID: 29388793
[TBL] [Abstract][Full Text] [Related]
6. Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastoma during bevacizumab therapy: a longitudinal MRI study.
Artzi M; Bokstein F; Blumenthal DT; Aizenstein O; Liberman G; Corn BW; Ben Bashat D
Eur J Radiol; 2014 Jul; 83(7):1250-1256. PubMed ID: 24809637
[TBL] [Abstract][Full Text] [Related]
7. [Correlation of serial MRI and histological findings following intra-tumor local chemotherapy for malignant brain tumor].
Shimura T; Nakazawa S; Takahashi H; Node Y; Tamai J; Kumazaki T
Gan To Kagaku Ryoho; 1994 Feb; 21(2):209-18. PubMed ID: 8311491
[TBL] [Abstract][Full Text] [Related]
8. Glioblastoma detected at the initial stage in its developmental process -case report-.
Oyama H; Ando Y; Aoki S; Kito A; Maki H; Hattori K; Tanahashi K
Neurol Med Chir (Tokyo); 2010; 50(5):414-7. PubMed ID: 20505302
[TBL] [Abstract][Full Text] [Related]
9. Apparent diffusion coefficient changes predict survival after intra-arterial bevacizumab treatment in recurrent glioblastoma.
Galla N; Chiang G; Chakraborty S; Singh R; John Tsiouris A; Boockvar J; Kovanlikaya I
Neuroradiology; 2017 May; 59(5):499-505. PubMed ID: 28343250
[TBL] [Abstract][Full Text] [Related]
10. Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients.
Zhang M; Gulotta B; Thomas A; Kaley T; Karimi S; Gavrilovic I; Woo KM; Zhang Z; Arevalo-Perez J; Holodny AI; Rosenblum M; Young RJ
Neuro Oncol; 2016 May; 18(5):735-43. PubMed ID: 26538618
[TBL] [Abstract][Full Text] [Related]
11. First report of tumor treating fields use in combination with bevacizumab in a pediatric patient: a case report.
O'Connell D; Shen V; Loudon W; Bota DA
CNS Oncol; 2017 Jan; 6(1):11-18. PubMed ID: 27918194
[TBL] [Abstract][Full Text] [Related]
12. Rapid malignant transformation of low-grade astrocytoma in a pregnant woman.
Hanada T; Rahayu TU; Yamahata H; Hirano H; Yoshioka T; Arita K
J Obstet Gynaecol Res; 2016 Oct; 42(10):1385-1389. PubMed ID: 27356501
[TBL] [Abstract][Full Text] [Related]
13. Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma.
Nguyen HS; Milbach N; Hurrell SL; Cochran E; Connelly J; Bovi JA; Schultz CJ; Mueller WM; Rand SD; Schmainda KM; LaViolette PS
AJNR Am J Neuroradiol; 2016 Dec; 37(12):2201-2208. PubMed ID: 27492073
[TBL] [Abstract][Full Text] [Related]
14. ADC quantification to classify patients candidate to receive bevacizumab treatment for recurrent glioblastoma.
Asenjo García B; Navarro Guirado F; Nagib Raya F; Vidal Denis M; Bravo Rodríguez F; Galán Montenegro P
Acta Radiol; 2020 Mar; 61(3):404-413. PubMed ID: 31357873
[No Abstract] [Full Text] [Related]
15. Decreased tumor apparent diffusion coefficient correlates with objective response of pediatric low-grade glioma to bevacizumab.
Hsu CH; Lober RM; Li MD; Partap S; Murphy PA; Barnes PD; Fisher PG; Yeom KW
J Neurooncol; 2015 May; 122(3):491-6. PubMed ID: 25758812
[TBL] [Abstract][Full Text] [Related]
16. Sustained focal antitumor activity of bevacizumab in recurrent glioblastoma.
Bähr O; Harter PN; Weise LM; You SJ; Mittelbronn M; Ronellenfitsch MW; Rieger J; Steinbach JP; Hattingen E
Neurology; 2014 Jul; 83(3):227-34. PubMed ID: 24928118
[TBL] [Abstract][Full Text] [Related]
17. Hypericin uptake: a prognostic marker for survival in high-grade glioma.
Ritz R; Müller M; Dietz K; Duffner F; Bornemann A; Roser F; Tatagiba M
J Clin Neurosci; 2008 Jul; 15(7):778-83. PubMed ID: 18394904
[TBL] [Abstract][Full Text] [Related]
18. Radiological Recurrence Patterns after Bevacizumab Treatment of Recurrent High-Grade Glioma: A Systematic Review and Meta-Analysis.
Cho SJ; Kim HS; Suh CH; Park JE
Korean J Radiol; 2020 Jul; 21(7):908-918. PubMed ID: 32524791
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
[TBL] [Abstract][Full Text] [Related]
20. Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: a multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma.
Ellingson BM; Kim E; Woodworth DC; Marques H; Boxerman JL; Safriel Y; McKinstry RC; Bokstein F; Jain R; Chi TL; Sorensen AG; Gilbert MR; Barboriak DP
Int J Oncol; 2015 May; 46(5):1883-92. PubMed ID: 25672376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
